McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin E. Noonan authored an article entitled, “Patent watch: Diagnostic patents at risk after Federal Circuit decisions” that appears in the May 20, 2016 online edition of Nature Reviews Drug Discovery. Patent claims to diagnostic methods have been endangered in the United States — but not elsewhere in the world — ever since the US Supreme Court handed down its decision in Mayo v. Prometheus Labs in 2013. In the latest example, Genetic Technologies Ltd v. Merial, the Federal Circuit has once again invalidated claims on genetic diagnostic methods, holding that the patent did not involve anything more than a routine application of natural laws. view the article
